1
|
Bijon J, Elahi S, Dubois M, Ghazal W, Courtin R, Panthier C, Gatinel D, Saad A. Descemet's membrane endothelial keratoplasty rejection after SARS-COV2 infection or vaccination: 2-year retrospective study. J Fr Ophtalmol 2024; 47:104117. [PMID: 38696860 DOI: 10.1016/j.jfo.2024.104117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Revised: 01/07/2024] [Accepted: 01/16/2024] [Indexed: 05/04/2024]
Abstract
PURPOSE To assess the incidence of Descemet's membrane endothelial keratoplasty (DMEK) rejection potentially associated with coronavirus disease 2019 (COVID-19) infection or vaccination, and its association with known rejection risk factors during the first two years of the pandemic. METHODS This retrospective study included patients with DMEK rejection between January 2020 and December 2021. Diagnostic criteria were based on symptoms, visual acuity, and other clinical assessments. Risk factors for graft rejection were considered, and a telephone survey was conducted to identify possible preceding COVID-19 infection or vaccination. RESULTS Of 58 patients, 44 were included. Six patients (14%) reported COVID-19 infection, with one immediate endothelial graft rejection (EGR) post-infection. After vaccine availability, 13 of 36 patients had EGR at an average of 2.7 months post-vaccination. Five (38%) had immediate EGR following vaccination, four of which had concomitant risk factors for rejection. CONCLUSION Although the risk of endothelial graft rejection (EGR) associated with COVID-19 infection or vaccination appears to be extremely low, there may be a causative relationship, especially in patients with pre-existing risk factors for EGR. A temporary increase in anti-rejection treatment following COVID-19 infection or vaccination is recommended, especially in patients with pre-existing risk factors, along with closer monitoring during the subsequent 4 to 8 weeks.
Collapse
Affiliation(s)
- J Bijon
- Department of Ophthalmology, Rothschild Foundation, Paris, France
| | - S Elahi
- Department of Ophthalmology, Rothschild Foundation, Paris, France
| | - M Dubois
- Department of Ophthalmology, Rothschild Foundation, Paris, France
| | - W Ghazal
- Department of Ophthalmology, Rothschild Foundation, Paris, France
| | - R Courtin
- Department of Ophthalmology, Rothschild Foundation, Paris, France
| | - C Panthier
- Department of Ophthalmology, Rothschild Foundation, Paris, France
| | - D Gatinel
- Department of Ophthalmology, Rothschild Foundation, Paris, France
| | - A Saad
- Department of Ophthalmology, Rothschild Foundation, Paris, France.
| |
Collapse
|
2
|
Ghomari C, Ouvrard E, Latgé A, Dubois M, Namer I. Apport de la TEMP/TDM osseuse dans le diagnostic d’un syndrome SAPHO au stade précoce : à propos d’un cas. Médecine Nucléaire 2023. [DOI: 10.1016/j.mednuc.2023.01.084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/06/2023]
|
3
|
Pilard CM, Dubois M, Gauthereau I, Robillard P, Dumas-De-La-Roque E, Renesme L, Guibert C. Celastrol: A new potential therapeutic option in pulmonary hypertension associated to bronchopulmonary dysplasia. Archives of Cardiovascular Diseases Supplements 2023. [DOI: 10.1016/j.acvdsp.2022.10.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
4
|
Lange M, Clarisse B, Leconte A, Dembélé KP, Lequesne J, Nicola C, Dubois M, Derues L, Gidron Y, Castel H, Joly F. Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. BMC Cancer 2022; 22:1308. [PMID: 36513991 PMCID: PMC9749352 DOI: 10.1186/s12885-022-10384-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 11/28/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The discovery of the importance of the immune system and its role in oncogenesis led to the development of immunotherapy, a treatment that represents a major advance in oncology management. Due to the recent nature of immunotherapy, little is known about its side effects and their impact on quality of life. To date, there is no published study that accurately assesses the impact of immunotherapy on cognition, mood and/or fatigue in patients treated for cancer, despite potential neurological toxicities. The purpose of this study is to prospectively assess the incidence of cognitive impairment and cognitive complaints among cancer patients naïve for immunotherapy without concomitant anti-cancer treatment. METHODS The Cog-Immuno trial is a multicentre longitudinal study addressing patients with cancer candidate to receive immunotherapy alone (n = 100). Immunotherapy treatment will include either anti-PD1/PDL1 or anti-CTLA4 monotherapy or combination therapy. Cognitive and quality of life assessment, electrocardiogram (ECG) and biological tests will be performed at baseline, thereafter 3, and 6 months after immunotherapy initiation. The primary endpoint is the proportion of patients treated by immunotherapy who will experience a decline in cognitive performances or in Montreal Cognitive Assessment (MoCA) score within 3 months after inclusion. Secondary endpoints concern: anxiety, depression, fatigue, clinical characteristics, biological data and neurophysiological measures (heart rate variability and hemispheric lateralization). A pre-clinical study will be conducted in cancer bearing mice receiving checkpoint inhibitors (ICI) with the evaluation of cognitive functions and emotional reactivity, collection of blood samples and investigation of neurobiological mechanisms from brain slices. DISCUSSION Assessing and understanding the incidence and the severity of cognitive impairment and its impact on quality of life in cancer patients treated by immunotherapy is a major issue. The results of this study will provide information on the impact of these treatments on cognitive functions in order to help the physicians in the choice of the treatment. TRIAL REGISTRATION NCT03599830, registered July 26, 2018. PROTOCOL VERSION Version 5.1 dated from 2020/10/02.
Collapse
Affiliation(s)
- Marie Lange
- grid.418189.d0000 0001 2175 1768Clinical Research Department, Centre François Baclesse, 14000 Caen, France ,grid.7429.80000000121866389Normandie Univ, UNICAEN, INSERM, ANTICIPE, 14000 Caen, France ,Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France
| | - Bénédicte Clarisse
- grid.418189.d0000 0001 2175 1768Clinical Research Department, Centre François Baclesse, 14000 Caen, France
| | - Alexandra Leconte
- grid.418189.d0000 0001 2175 1768Clinical Research Department, Centre François Baclesse, 14000 Caen, France
| | - Kléouforo-Paul Dembélé
- Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France ,grid.7429.80000000121866389Normandie University, UNIROUEN, INSERM, U1245, Cancer and Brain Genomics, 76000 Rouen, France ,grid.503198.6Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Justine Lequesne
- grid.418189.d0000 0001 2175 1768Clinical Research Department, Centre François Baclesse, 14000 Caen, France ,grid.7429.80000000121866389Normandie Univ, UNICAEN, INSERM, ANTICIPE, 14000 Caen, France ,Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France
| | - Celeste Nicola
- Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France ,grid.7429.80000000121866389Normandie University, UNIROUEN, INSERM, U1245, Cancer and Brain Genomics, 76000 Rouen, France ,grid.503198.6Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Martine Dubois
- Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France ,grid.7429.80000000121866389Normandie University, UNIROUEN, INSERM, U1245, Cancer and Brain Genomics, 76000 Rouen, France ,grid.503198.6Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Laurence Derues
- Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France ,grid.7429.80000000121866389Normandie University, UNIROUEN, INSERM, U1245, Cancer and Brain Genomics, 76000 Rouen, France ,grid.503198.6Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Yori Gidron
- grid.18098.380000 0004 1937 0562Dept. of Nursing, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel
| | - Hélène Castel
- Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France ,grid.7429.80000000121866389Normandie University, UNIROUEN, INSERM, U1245, Cancer and Brain Genomics, 76000 Rouen, France ,grid.503198.6Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Florence Joly
- grid.418189.d0000 0001 2175 1768Clinical Research Department, Centre François Baclesse, 14000 Caen, France ,grid.7429.80000000121866389Normandie Univ, UNICAEN, INSERM, ANTICIPE, 14000 Caen, France ,Cancer & Cognition Platform, Ligue Contre le Cancer, 14000 Caen, France ,grid.418189.d0000 0001 2175 1768Medical oncology department, Centre François Baclesse, 14000 Caen, France
| |
Collapse
|
5
|
Chernyavsky SM, Dubois M, Korobkina E, Lychagin EV, Muzychka AY, Nekhaev GV, Nesvizhevsky VV, Nezvanov AY, Strelkov AV, Zhernenkov KN. Enhanced directional extraction of very cold neutrons using a diamond nanoparticle powder reflector. Rev Sci Instrum 2022; 93:123302. [PMID: 36586889 DOI: 10.1063/5.0124833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2022] [Accepted: 11/09/2022] [Indexed: 06/17/2023]
Abstract
For more than a decade, detonation nanodiamond (DND) powders have been actively studied as a material for efficient reflectors of very cold neutrons (VCNs) and cold neutrons. In this work, we experimentally demonstrate, for the first time, the possibility of enhanced directional extraction of a VCN beam using a reflector made of fluorinated DND powder. With respect to the theoretical flux calculated from an isotropic source at the bottom of the reflector cavity, the gain in the VCN flux density along the beam axis is ∼10 for the neutron velocities of ∼57 and ∼75 m/s. The use of such reflectors for enhanced directional extraction of VCN from neutron sources will make it possible to noticeably increase the neutron fluxes delivered to experiments and expand the scope of VCN applications.
Collapse
Affiliation(s)
- S M Chernyavsky
- National Research Center "Kurchatov Institute," 123182 Moscow, Russia
| | - M Dubois
- Université Clermont Auvergne, Clermont Auvergne INP, Institut de Chimie de Clermont-Ferrand (ICCF UMR 6296), CNRS, 63178 Auvergne, France
| | - E Korobkina
- NC State University, Raleigh, North Carolina 27695-710, USA
| | - E V Lychagin
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - A Yu Muzychka
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - G V Nekhaev
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | | | - A Yu Nezvanov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - A V Strelkov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - K N Zhernenkov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| |
Collapse
|
6
|
Pilard C, Dubois M, Gauthereau I, Kobersy J, Dumas-de-la-Roque E, Renesme L, Guibert C. Effect of celastrol on pulmonary hypertension associated to bronchopulmonary dysplasia. Rev Mal Respir 2022. [DOI: 10.1016/j.rmr.2022.02.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
Deml M, Jungo K, Rachamin Y, Gicquel F, Dubois M, Bertato S, Dubois J, Senn O, Streit S. Continuity of care during the COVID-19 pandemic: Qualitative results from a mixed-methods study. Eur J Public Health 2021. [PMCID: PMC8574681 DOI: 10.1093/eurpub/ckab164.134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Decreases in health service use were observed globally during the COVID-19 pandemic. In the quantitative part of this mixed-methods study, we documented similar trends in Switzerland, with a retrospective cohort study showing a 15-20% decrease in general practitioner (GP) consultations/chronic disease monitoring in spring 2020. These changes need to be understood, particularly for individuals at risk of COVID-19 complications, as many have conditions requiring regular monitoring. Methods With a mixed-methods design, we examine continuity of care for at-risk groups (people: ≥65-years-old, with cancer, diabetes, respiratory disease, etc.) between Mar-2020 and Apr-2021. Following quantitative analyses, we qualitatively studied changes in GP/patient practices thru semi-structured interviews with 23 GPs and 36 at-risk patients. We here focus on thematically analyzed qualitative results. Results Qualitative data helped explain observed reductions in consultations/monitoring: 1) some patients were discouraged to seek care by official recommendations and/or GPs during the first semi-shutdown; 2) some patients perceived GP offices as closed/overburdened; 3) some patients feared contracting coronavirus; 4) some patients sought alternatives to traditional primary care consultations (e.g., tele-consultations, consulting pharmacists/other professionals, self-reliance). Many patients did not feel that there was discontinuity of their cares. GPs commonly described feeling like an underutilized resource during the pandemic and explained how they could have been mobilized for population needs. Conclusions During the first wave, there was a mismatch between 1) GPs' reported availability/preparedness to adequately care for at-risk patients, and 2) some GPs discouraging at-risk patients to come for consultations, at-risk patients' perceptions that their care was not “urgent” in a pandemic setting, and patient perceptions that GPs were otherwise unavailable/overburdened. Key messages Qualitative data offer explanations for health service use reductions during the COVID-19 pandemic. Results provide potential paths forward and highlight GP views of being an underutilized resource.
Collapse
Affiliation(s)
- M Deml
- Institute of Sociological Research, Department of Sociology, University of Geneva, Geneva, Switzerland
| | - K Jungo
- Institute of Primary Health Care, University of Bern, Bern, Switzerland
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland
| | - Y Rachamin
- Institute of Primary Care, University of Zurich and University Hospital Zurich, Zurich, Switzerland
| | - F Gicquel
- Institute of Sociological Research, Department of Sociology, University of Geneva, Geneva, Switzerland
| | - M Dubois
- Institute of Sociological Research, Department of Sociology, University of Geneva, Geneva, Switzerland
| | - S Bertato
- Institute of Primary Health Care, University of Bern, Bern, Switzerland
- Graduate School for Health Sciences, University of Bern, Bern, Switzerland
| | - J Dubois
- Institute of Family Medicine, University of Fribourg, Fribourg, Switzerland
| | - O Senn
- Institute of Primary Care, University of Zurich and University Hospital Zurich, Zurich, Switzerland
| | - S Streit
- Institute of Primary Health Care, University of Bern, Bern, Switzerland
| |
Collapse
|
8
|
Migueres M, Lhomme S, Trémeaux P, Dimeglio C, Ranger N, Latour J, Dubois M, Nicot F, Miedouge M, Mansuy JM, Izopet J. Evaluation of two RT-PCR screening assays for identifying SARS-CoV-2 variants. J Clin Virol 2021; 143:104969. [PMID: 34509927 PMCID: PMC8411575 DOI: 10.1016/j.jcv.2021.104969] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 08/20/2021] [Accepted: 08/25/2021] [Indexed: 01/26/2023]
Abstract
Background The recent emergence of new SARS CoV-2 variants (variants of concern, VOC) that spread rapidly and may lead to immune escape has emphasized the urgent need to monitor and control their spread. Methods We analyzed 2018 SARS-CoV-2 positive specimens collected between February 9 and March 22, 2021 using the Thermofisher® TaqPath™ COVID-19 CE-IVD RT-PCR kit (TaqPath) and the ID solutions® ID™ SARS-CoV-2/UK/SA Variant Triplex RT-PCR (ID triplex) assay to screen for VOCs. Results The ID triplex assay identified 62.8% of them as VOCs: 61.8% B.1.1.7 and 0.9% B.1.351/P.1. The agreement between the ID triplex results for B.1.1.7 and the TaqPath S gene target failure (SGTF)/ S gene target late detection (SGTL) profile for this variant agreed very well (k = 0.86). A low virus load was the main cause of discrepancies. Sequencing discordant results with both assays indicated that the TaqPath assay detected the B.1.1.7 lineage slightly better. Both assays suggested that the virus loads of B.1.1.7 variants were significantly higher than those of non-B.1.1.7 strains. Only 10/20 B1.351/P.1 strains detected with the ID triplex assay were confirmed by sequencing. Conclusions We conclude that the SGTF/SGTL profiles identified using the TaqPath assay and ID triplex results are suitable for detecting the B.1.1.7 lineage. The ID triplex assay, which rapidly determines all three current VOCs simultaneously, could be a valuable tool for limiting virus spread by supporting contact-tracing and isolation.
Collapse
Affiliation(s)
- M Migueres
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France.
| | - S Lhomme
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France
| | - P Trémeaux
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - C Dimeglio
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - N Ranger
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - J Latour
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - M Dubois
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - F Nicot
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - M Miedouge
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - J M Mansuy
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France
| | - J Izopet
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051, Toulouse 31300, France; Université Toulouse III Paul-Sabatier, Toulouse, France
| |
Collapse
|
9
|
Castel H, Laillet De Montulle E, Dubois M, Ferracci F, Mutel A, Dembele K, Desrues L, Derrey S, Langlois O, Chever O, Gandolfo P, Morin F. P13.10 Chemoattraction of glioma cells in a local hydrogel trap and immune control associated with improved survival and cognitive functions in a mouse model of glioblastoma resection. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Glioblastoma (GB) is the most aggressive brain primary tumor. The prognosis remains poor mainly due to the invasiveness of glioma cells, radio and/or chemoresistance and GB-induced immunosuppressive environment. Here, we propose to use a local delivery system based on a biocompatible hydrogel containing the chemopeptide urotensin II (hUII) or a biased synthetic analog DAB8-hUII, to “trap” GB cells, and/or to control immune cells expressing its G protein-coupled receptor UT, leading to tumor regression and neurological benefit, in a mouse model of GB resection.
MATERIAL AND METHODS
In vitro, invasion towards UII/analog across different hydrogels or glue of human or murine GB-GFP cell lines was evaluated in Boyden chamber and cloning ring assays. In vivo GB cells were intrastriatally xenografted, then resected while hydrogel- or glue-containing UII/analog was injected in the cavity resection. Behavioral tests, brain immunohistochemical analyses and mouse survival were then investigated.
RESULTS
In vitro, invasive capacity of human U87 and 42MG or murine GL261 and CT2A GB cells was stimulated by UII loaded into hydrogel-based hyaluronic acid supplemented with collagen or other chemicals, PNIPAAm-PEG, or thrombin-fibrin glue. In vivo, injection of UII- or DAB8-hUII-loaded glue into the cavity resection of GL261 and CT2A GB in C57BL/6 mice significantly improved survival compared with tumor and resected experimental conditions. Neurological status was also tested before and after GB resection. We found that GL261 and CT2A cell-bearing mice expressed altered spontaneous activity, emotion and cognitive functions. Intracavity injection of the glue improved resignation and anxiety and increased motor activity and cognition with a best cognitive recovery with hUII and DAB-8-hUII-loaded glue groups. Ex vivo brain analyses revealed high expression of UT and UII in some GB GFP-positive cells and macrophages within GB core and at the interface with the normal brain, GB cells expressing UT migrating along tortuous podocalyxin+ vascular components. In brains bearing hydrogel/hUII glue, vascularization appears modified and GFAP+ astrocytes and F4/80+ macrophages were highly recruited in the border of the cavity, compared with the other conditions.
CONCLUSION
A local glue containing UII may trap GB cells and remodel the tumor microenvironment responsible for survival and cognitive improvements, providing new option in the therapeutic arsenal of GB.
Collapse
Affiliation(s)
- H Castel
- INSERM U1239, Mont-Saint-Aignan, France
| | | | - M Dubois
- INSERM U1239, Mont-Saint-Aignan, France
| | | | - A Mutel
- INSERM U1239, Mont-Saint-Aignan, France
| | - K Dembele
- INSERM U1239, Mont-Saint-Aignan, France
| | - L Desrues
- INSERM U1239, Mont-Saint-Aignan, France
| | - S Derrey
- Neurosurgery Service, Rouen CHU Hospital, Rouen, France
| | - O Langlois
- Inserm U1239, Neurosurgery Service, Rouen CHU Hospital, Mont-Saint-Aignan, France
| | - O Chever
- INSERM U1239, Mont-Saint-Aignan, France
| | | | - F Morin
- INSERM U1239, Mont-Saint-Aignan, France
| |
Collapse
|
10
|
Ziranu P, Aimola V, Pretta A, Cerrone G, Persano M, Liscia N, Dubois M, Migliari M, Sarais F, Cimbro E, Parrino A, Spanu D, Mariani S, Donisi C, Pinna G, Pusceddu V, Puzzoni M, Lai E, Faa G, Scartozzi M. 490P New horizons in metastatic colorectal cancer: Role of CD44 expression. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Nicola C, Dubois M, Campart C, Al Sagheer T, Desrues L, Schapman D, Galas L, Lange M, Joly F, Castel H. The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice. Cancers (Basel) 2021; 13:cancers13143518. [PMID: 34298734 PMCID: PMC8304001 DOI: 10.3390/cancers13143518] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2021] [Revised: 07/06/2021] [Accepted: 07/08/2021] [Indexed: 01/08/2023] Open
Abstract
Simple Summary Cognitive side effects and fatigue after cancer treatment now constitute a major challenge in oncology. Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are next-generation therapies improving metastatic castration-resistant prostate cancer (mCRPC) patient survival, but also associated with neurological disturbances. We developed a behavioral 17 months-aged and castrated mouse model receiving AAP or ENZ for 5 days per week for six weeks. We establish that ENZ impacts locomotor and explorative behaviors, and strength capacity likely by preventing binding of central synthetized androgens to androgen receptors expressed by dopamine neurons of the Substantia Nigra and the Ventral Tegmentum. ENZ also reduces the cognitive score, associated with less neuronal activity in dorsal hippocampal areas. This demonstrates ENZ-specific consequences on motivation to exploration and cognition, being of particular importance for future management of elderly prostate cancer patients and their quality of life. Abstract Cognitive side effects after cancer treatment threatening quality of life (QoL) constitute a major challenge in oncology. Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are examples of next-generation therapy (NGT) administered to metastatic castration-resistant prostate cancer (mCRPC) patients. NGT significantly improved mCRPC overall survival but neurological side effects such as fatigue and cognitive impairment were reported. We developed a behavioral 17 months-aged and castrated mouse model receiving per os AAP or ENZ for 5 days per week for six consecutive weeks. ENZ exposure reduced spontaneous activity and exploratory behavior associated with a decreased tyrosine hydroxylase (TH)-dopaminergic activity in the substantia nigra pars compacta and the ventral tegmental area. A decrease in TH+-DA afferent fibers and Phospho-DARPP32-related dopaminergic neuronal activities in the striatum and the ventral hippocampus highlighted ENZ-induced dopaminergic regulation within the nigrostriatal and mesolimbocortical pathways. ENZ and AAP treatments did not substantially modify spatial learning and memory performances, but ENZ led to a thygmotaxis behavior impacting the cognitive score, and reduced c-fos-related activity of NeuN+-neurons in the dorsal hippocampus. The consequences of the mCRPC treatment ENZ on aged castrated mouse motivation to exploration and cognition should make reconsider management strategy of elderly prostate cancer patients.
Collapse
Affiliation(s)
- Celeste Nicola
- Normandie University, UNIROUEN, INSERM, U1239 DC2N, 76000 Rouen, France; (C.N.); (M.D.); (C.C.); (T.A.S.); (L.D.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
- Cancer and Cognition Platform, Ligue Nationale contre le Cancer, 14000 Caen, France; (M.L.); (F.J.)
| | - Martine Dubois
- Normandie University, UNIROUEN, INSERM, U1239 DC2N, 76000 Rouen, France; (C.N.); (M.D.); (C.C.); (T.A.S.); (L.D.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
- Cancer and Cognition Platform, Ligue Nationale contre le Cancer, 14000 Caen, France; (M.L.); (F.J.)
| | - Cynthia Campart
- Normandie University, UNIROUEN, INSERM, U1239 DC2N, 76000 Rouen, France; (C.N.); (M.D.); (C.C.); (T.A.S.); (L.D.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
- Cancer and Cognition Platform, Ligue Nationale contre le Cancer, 14000 Caen, France; (M.L.); (F.J.)
| | - Tareq Al Sagheer
- Normandie University, UNIROUEN, INSERM, U1239 DC2N, 76000 Rouen, France; (C.N.); (M.D.); (C.C.); (T.A.S.); (L.D.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
| | - Laurence Desrues
- Normandie University, UNIROUEN, INSERM, U1239 DC2N, 76000 Rouen, France; (C.N.); (M.D.); (C.C.); (T.A.S.); (L.D.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
- Cancer and Cognition Platform, Ligue Nationale contre le Cancer, 14000 Caen, France; (M.L.); (F.J.)
| | - Damien Schapman
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
- Normandie University, UNIROUEN, INSERM, PRIMACEN, 76000 Rouen, France
| | - Ludovic Galas
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
- Normandie University, UNIROUEN, INSERM, PRIMACEN, 76000 Rouen, France
| | - Marie Lange
- Cancer and Cognition Platform, Ligue Nationale contre le Cancer, 14000 Caen, France; (M.L.); (F.J.)
- Centre François Baclesse, Clinical Research Department, 14000 Caen, France
- Normandie University, UNICAEN, INSERM, U1086 ANTICIPE, 14000 Caen, France
| | - Florence Joly
- Cancer and Cognition Platform, Ligue Nationale contre le Cancer, 14000 Caen, France; (M.L.); (F.J.)
- Centre François Baclesse, Clinical Research Department, 14000 Caen, France
- Normandie University, UNICAEN, INSERM, U1086 ANTICIPE, 14000 Caen, France
- University Hospital of Caen, 14000 Caen, France
| | - Hélène Castel
- Normandie University, UNIROUEN, INSERM, U1239 DC2N, 76000 Rouen, France; (C.N.); (M.D.); (C.C.); (T.A.S.); (L.D.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France; (D.S.); (L.G.)
- Cancer and Cognition Platform, Ligue Nationale contre le Cancer, 14000 Caen, France; (M.L.); (F.J.)
- Normandie University, UNIROUEN, INSERM, DC2N, Team Astrocyte and Vascular Niche, Place Emile Blondel, CEDEX, 76821 Mont-Saint-Aignan, France
- Correspondence: ; Tel.: +33-2-35-14-66-23
| |
Collapse
|
12
|
Pretta A, Donisi C, Persano M, Pinna G, Cimbro E, Parrino A, Migliari M, Dubois M, Liscia N, Mariani S, Lai E, Puzzoni M, Pusceddu V, Ziranu P, Scartozzi M. P-127 Lymphocyte to monocyte ratio as a prognostic factor in stage IV pancreatic ductal adenocarcinoma naive patients before gemcitabine-nab-paclitaxel chemotherapy. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
13
|
Pretta A, Pinna G, Donisi C, Persano M, Cimbro E, Parrino A, Migliari M, Dubois M, Liscia N, Mariani S, Lai E, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M. P-128 Influence of anti-diabetic medications on the outcomes of patients with pancreatic ductal adenocarcinoma and type 2 diabetes mellitus. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
14
|
Pretta A, Persano M, Pinna G, Donisi C, Cimbro E, Parrino A, Migliari M, Dubois M, Mariani S, Liscia N, Lai E, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M. P-129 Concomitant RAS and BRAF mutations: Impact on overall survival and progression free survival in metastatic colorectal cancer patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Felten R, Dubois M, Ugarte-Gil MF, Fort J, Pijnenburg L, Chaudier A, Kawka L, Costecalde C, Bergier H, Chatelus E, Javier RM, Sordet C, Gottenberg JE, Sibilia J, Fuentes-Silva Y, Arnaud L. POS1190 EXPECTATIONS AND POTENTIAL CONCERNS OF PATIENTS WITH AUTOIMMUNE AND RHEUMATIC DISEASES REGARDING VACCINATION AGAINST SARS-CoV-2 (COVID-19): THE WORLDWIDE ONLINE VAXICOV STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Vaccination is an important and effective tool to prevent infections in the general population as well as in patients with systemic autoimmune or inflammatory rheumatic diseases (AIIRDs) who may be at increased risk of serious infection. While the global race for vaccines against COVID-19 has already lead to first authorizations and vaccinations in some countries, multiple questions arise for access and provisions as well as for the acceptance of vaccine policies by immunocompromised patients.Objectives:We conducted an international survey about expectations and potential concerns regarding SARS-CoV-2 vaccine in patients with AIIRDs and healthcare professionals.Methods:The online study consisted of 57 questions which addressed determinants associated with SARS-2-CoV-2 vaccine willingness. Dissemination was ensured through social media and patient associations between December 12 and December 21, 2020.Results:The study included 1266 patients with AIIRDs and 265 healthcare professionals from 56 countries. SARS-CoV-2 vaccine willingness was reported by 54.2% of AIIRD patients (uncertainty in 32.2% and unwillingness in 13.6%) and 74.0% of healthcare professionals. In patients, the willingness to get vaccinated increased significantly with age (p<0.0001) and was strongly associated with the fear to be infected by SARS-CoV-2 (p<0.0001) or to develop severe COVID19 (p<0.0001) but not with presence of additional comorbidities (p=0.71) or immunocompromised status (p=0.94). The most trusted healthcare professional regarding the recommendation to get vaccinated against COVID-19 was their specialist (rheumatologist, internist, etc.) for 69.9%. Vaccine unwillingness was low (7.9%) among healthcare professionals and willingness was significantly increased in those who had been vaccinated against influenza in the last 3 years (p=0.01).Subject groupsPatientsHealthcare professionalsN1266265Age (years), median [IQR25-75]50 [40-61]40 [32.5-53]Female, n (%)1141 (90.1%)150 (56.6%)Male, n (%)115 (9.9%)115 (43.4%)Country, n (%) France320 (25.3%)159 (60%) UK345(27.3%)4 (1.5%) Chile123 (9.7%)4 (1.5%) USA114 (9.0%)7 (2.6%) Venezuela43 (3.4%)26 (9.8%) Spain57 (4.5%)3 (1.1%) Mexico53 (4.2%)3 (1.1%) Argentina45 (3.6%)8 (3.0%) Other*166 (13.1%)51 (19.2%)Rheumatic diagnosis, n (%)1266- Systemic lupus erythematosus492 (38.9%)- Spondyloarthritis176 (13.9%)- Rheumatoid arthritis160 (12.6%)- Giant cell arteritis / Polymyalgia rheumatica144 (11.4%)- Primary anti-phospholipid syndrome64 (5.1%)- Inflammatory myositis62 (4.9%)- Relapsing polychondritis45 (3.6%)- Other**123 (9.7%)--Health professionals, n (%)-265 Doctor-203 (76.6%) Nurse (or equivalent)-23 (8.7%) Nursing assistant-11 (4.2%) Other***-28 (10.6%)Associated comorbidities, n (%) Diabetes69 (5.5%)6 (2.3%) Hypertension267 (21.1%)24 (9.1%) Myocardial infarction, stroke, transient stroke60 (4.7%)1 (0.4%) Respiratory disease (asthma, chronic bronchitis, emphysema, etc.)169 (13.3%)13 (4.9%)Renal failure47 (3.7%)1 (0.4%)Obesity (BMI > 30)228 (18.0%)18 (6.8%)At least one associated comorbidity, n (%)588 (46.4%)50 (18.9%)Smoker, n (%)128 (10.2%)22 (8.3%) Current411 (32.7%)51 (19.2%) Past719 (57.1%)192 (72.5%) NeverUse of oral glucocorticoids, n (%)551 (56.1%)3 (1.1%)Immunocompromised$, n (%)770 (60.8%)0On a 0 to 10 scale, median8 (6-10)5 (3-8)[IQR25-75]9 (7-10)5 (1-8)−Afraid to get infected by SARS-CoV-2−Afraid to get a severe COVID-19Willing to get vaccinated (Yes / uncertain / No), %54.2 / 32.2 / 13.674.0 / 18.1 / 7.9Vaccine hesitancy, n (%)357 (28.2%)59 (22.3%)Conclusion:Data from this study are crucial to understand the main expectations and concerns regarding SARS-CoV-2 vaccination in patients with AIIRDs and healthcare workers and allow the identification of valuable strategies to increase vaccine coverage in those populations.Acknowledgements:We wish to acknowledge the crucial role of the following patient associations: LupusEurope (tweeter: @LupusEurope), Agrupacion Lupus Chile (@Lupus_Chile), RarasNoInvisibles (@Noinvisibles), Lupus UK, Lupus France, SPONDYL’ASSO, Spondyl(O)action, AFL+, in the dissemination of the survey. We are indebted to Gonzalo Tobar Carrizo (@pinkycito) for the Spanish translation of the survey, all patients, families, and health professionals for their kind participation in our study. We wish to thank Ms. Sylvie Thuong for her invaluable assistance.Disclosure of Interests:Renaud FELTEN Speakers bureau: Pfizer, Maxime Dubois: None declared, Manuel F. Ugarte-Gil Speakers bureau: Janssen and Pfizer, Jérémy Fort: None declared, Luc PIJNENBURG: None declared, Aurore Chaudier: None declared, Lou Kawka: None declared, Charlotte Costecalde: None declared, Hugo Bergier: None declared, Emmanuel Chatelus: None declared, Rose-Marie Javier: None declared, Christelle Sordet: None declared, Jacques-Eric Gottenberg Speakers bureau: Pfizer and Astra-Zeneca, Jean Sibilia Speakers bureau: Pfizer, Yurilis Fuentes-Silva: None declared, Laurent Arnaud Speakers bureau: Pfizer and Astra-Zeneca.
Collapse
|
16
|
Naouri M, Dahan S, Le Pillouer Prost A, Coutant-Foulc P, Raimbault C, Cucurella F, Beille L, Creusot M, Baspeyras M, Darchy M, Khallouf R, Cartier H, Baratte I, Dubois M, Cogrel O, Laubach H. Good tolerance of hyaluronic acid injections during the period of the COVID-19 pandemic: observing a cohort of 1093 patients in a prospective, observational real-life study. J Eur Acad Dermatol Venereol 2021; 35:e432-e433. [PMID: 33834559 PMCID: PMC8250514 DOI: 10.1111/jdv.17271] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 03/12/2021] [Accepted: 03/24/2021] [Indexed: 11/30/2022]
Affiliation(s)
- M Naouri
- Centre de Dermatologie, Esthétique et Laser de Nogent-sur-Marne, Nogent-sur-Marne, France.,Centre Laser Universitaire, Service de Dermatologie, Hôpital St Louis, CHU AP-HP Nord - Université de Paris, Paris, France
| | - S Dahan
- Centre de Dermatologie, Esthétique et Laser de Toulouse, Toulouse, France
| | | | - P Coutant-Foulc
- Centre Dermatologique et Esthétique de la Femme, Nantes, France
| | - C Raimbault
- Cabinet de Dermatologie, Esthétique et Laser de Metz, Metz, France
| | - F Cucurella
- Cabinet de Dermatologie, Esthétique et Laser d'Aix, Aix les Milles, France
| | - L Beille
- Cabinet de Dermatologie, Esthétique et Laser de Meylan, Meylan, France
| | - M Creusot
- Centre Dermatologique du Roy, Lasne - Plancenoit, Belgium
| | - M Baspeyras
- Cabinet de Dermatologie, Esthétique et Laser de Bordeaux, Cauderan, France
| | - M Darchy
- Centre de Dermatologie, Esthétique et Laser d'Orléans, Orléans, France
| | - R Khallouf
- Centre de Dermatologie, Esthétique et Laser de Tours, Tours, France
| | - H Cartier
- Centre médical Saint Jean, Arras, France
| | - I Baratte
- Cabinet de Dermatologie, Esthétique et Laser de Champagne au Mont d'Or, Champagne au Mont d'Or, France
| | - M Dubois
- Cabinet de Dermatologie, Esthétique et Laser de Sanary sur Mer, Sanary sur Mer, France
| | - O Cogrel
- Unité de Dermatologie Chirurgicale et Interventionnelle, Service de Dermatologie, CHU de Bordeaux, France
| | - H Laubach
- Centre Laser MD, Strasbourg, France.,Consultation Laser, Service de Dermatologie, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | | |
Collapse
|
17
|
Falcon T, Batisse N, Dubois M, Guérin K, Jourdan A, Groult H. Micro-texturing by femtosecond laser ablation of a carbonaceous anode for production of fluorine by electrolysis. J Fluor Chem 2021. [DOI: 10.1016/j.jfluchem.2021.109746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Barragué H, Fontaine J, Abravanel F, Mauré E, Péron JM, Alric L, Dubois M, Izopet J, Champagne E. Mobilization of γδ T Cells and IL-10 Production at the Acute Phase of Hepatitis E Virus Infection in Cytomegalovirus Carriers. J Immunol 2021; 206:1027-1038. [PMID: 33483348 DOI: 10.4049/jimmunol.2000187] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 12/26/2020] [Indexed: 12/12/2022]
Abstract
Alterations in the γδ T cell compartment have been reported in immunocompromised individuals infected with hepatitis E virus (HEV)-g3. We now report the analysis of blood γδ T cells from acutely HEV-infected individuals in the absence of immunosuppression. In these patients, non-Vδ2 (ND2) γδ T cells outnumbered otherwise predominant Vδ2 cells selectively in human CMV (HCMV)-seropositive patients and were higher than in HCMVpos controls, mimicking HCMV reactivation, whereas their serum was PCR-negative for HCMV. Stimulation of their lymphocytes with HEV-infected hepatocarcinoma cells led to an HEV-specific response in γδ subsets of HCMVpos individuals. HEV infection was associated with a lowered expression of TIGIT, LAG-3, and CD160 immune checkpoint markers on ND2 effector memory cells in HCMVneg but not in HCMVpos HEV patients. γδ cell lines, predominantly ND2, were generated from patients after coculture with hepatocarcinoma cells permissive to HEV and IL-2/12/18. Upon restimulation with HEV-infected or uninfected cells and selected cytokines, these cell lines produced IFN-γ and IL-10, the latter being induced by IL-12 in IFN-γ-producing cells and upregulated by HEV and IL-18. They were also capable of suppressing the proliferation of CD3/CD28-activated CD4 cells in transwell experiments. Importantly, IL-10 was detected in the plasma of 10 of 10 HCMVpos HEV patients but rarely in controls or HCMVneg HEV patients, implying that γδ cells are probably involved in IL-10 production at the acute phase of infection. Our data indicate that HEV mobilizes a pool of ND2 memory cells in HCMV carriers, promoting the development of an immunoregulatory environment.
Collapse
Affiliation(s)
- Hugo Barragué
- Université Toulouse III Paul-Sabatier, F-31024 Toulouse, France.,Centre de Physiopathologie de Toulouse Purpan, INSERM-U1043, CNRS-UMR5282, F-31024 Toulouse, France
| | - Jessica Fontaine
- Université Toulouse III Paul-Sabatier, F-31024 Toulouse, France.,Centre de Physiopathologie de Toulouse Purpan, INSERM-U1043, CNRS-UMR5282, F-31024 Toulouse, France
| | - Florence Abravanel
- Centre de Physiopathologie de Toulouse Purpan, INSERM-U1043, CNRS-UMR5282, F-31024 Toulouse, France.,CHU Toulouse, Hôspital Purpan, Laboratoire de Virologie, Centre National de Référence Hépatite E, F-31059 Toulouse, France; and
| | - Emilie Mauré
- Centre de Physiopathologie de Toulouse Purpan, INSERM-U1043, CNRS-UMR5282, F-31024 Toulouse, France
| | - Jean-Marie Péron
- Pôle Hospitalo-Universitaire des Maladies de l'Appareil Digestif, Hôspital Rangueil, F-31059 Toulouse, France
| | - Laurent Alric
- Pôle Hospitalo-Universitaire des Maladies de l'Appareil Digestif, Hôspital Rangueil, F-31059 Toulouse, France
| | - Martine Dubois
- CHU Toulouse, Hôspital Purpan, Laboratoire de Virologie, Centre National de Référence Hépatite E, F-31059 Toulouse, France; and
| | - Jacques Izopet
- Université Toulouse III Paul-Sabatier, F-31024 Toulouse, France.,Centre de Physiopathologie de Toulouse Purpan, INSERM-U1043, CNRS-UMR5282, F-31024 Toulouse, France.,CHU Toulouse, Hôspital Purpan, Laboratoire de Virologie, Centre National de Référence Hépatite E, F-31059 Toulouse, France; and
| | - Eric Champagne
- Université Toulouse III Paul-Sabatier, F-31024 Toulouse, France; .,Centre de Physiopathologie de Toulouse Purpan, INSERM-U1043, CNRS-UMR5282, F-31024 Toulouse, France
| |
Collapse
|
19
|
Nicot F, Dimeglio C, Migueres M, Jeanne N, Latour J, Abravanel F, Ranger N, Harter A, Dubois M, Lameiras S, Baulande S, Chapuy-Regaud S, Kamar N, Lhomme S, Izopet J. Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes. Front Microbiol 2021; 11:634430. [PMID: 33584599 PMCID: PMC7875884 DOI: 10.3389/fmicb.2020.634430] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Accepted: 12/30/2020] [Indexed: 12/27/2022] Open
Abstract
Hepatitis E virus (HEV) genotype 3 is the most common genotype linked to HEV infections in Europe and America. Three major clades (HEV-3.1, HEV-3.2, and HEV-3.3) have been identified but the overlaps between intra-subtype and inter-subtype p-distances make subtype classification inconsistent. Reference sequences have been proposed to facilitate communication between researchers and new putative subtypes have been identified recently. We have used the full or near full-length HEV-3 genome sequences available in the Genbank database (April 2020; n = 503) and distance analyses of clades HEV-3.1 and HEV-3.2 to determine a p-distance cut-off (0.093 nt substitutions/site) in order to define subtypes. This could help to harmonize HEV-3 genotyping, facilitate molecular epidemiology studies and investigations of the biological and clinical differences between HEV-3 subtypes.
Collapse
Affiliation(s)
- Florence Nicot
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France
| | - Chloé Dimeglio
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France.,INSERM, U1043, Toulouse, France
| | - Marion Migueres
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France.,INSERM, U1043, Toulouse, France
| | - Nicolas Jeanne
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France
| | - Justine Latour
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France
| | - Florence Abravanel
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France.,INSERM, U1043, Toulouse, France.,Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| | - Noémie Ranger
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France
| | - Agnès Harter
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France
| | - Martine Dubois
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France
| | - Sonia Lameiras
- Institut Curie Genomics of Excellence Platform, Institut Curie Research Center, Paris, France
| | - Sylvain Baulande
- Institut Curie Genomics of Excellence Platform, Institut Curie Research Center, Paris, France
| | - Sabine Chapuy-Regaud
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France.,INSERM, U1043, Toulouse, France.,Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| | - Nassim Kamar
- INSERM, U1043, Toulouse, France.,Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France.,CHU de Toulouse, Hôpital Rangueil, Service de Néphrologie, Dialyse et Transplantation d'Organe, Toulouse, France
| | - Sébastien Lhomme
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France.,INSERM, U1043, Toulouse, France.,Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| | - Jacques Izopet
- CHU de Toulouse, Hôpital Purpan, Laboratoire de Virologie, Centre National de Référence du Virus de l'Hépatite E, Toulouse, France.,INSERM, U1043, Toulouse, France.,Department of Virology, Université Toulouse III Paul-Sabatier, Toulouse, France
| |
Collapse
|
20
|
Dubois M, Abi Rached H, Escande A, Dezoteux F, Darloy F, Jouin A, Kyheng M, Labreuche J, Mirabel X, Mortier L. Évaluation du traitement par radiothérapie exclusive du carcinome de Merkel au stade localisé : étude rétrospective sur 53 patients. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
21
|
Boileau M, Dubois M, Abi Rached H, Escande A, Mirabel X, Mortier L. Radiothérapie exclusive des carcinomes de Merkel péri-oculaires localisés. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
22
|
Cardouat G, Douard M, Roubenne L, Kmecova S, Robillard P, Guignabert C, Tu L, Delcambre F, Dubois M, Marthan R, Muller B, Guibert C, Freund-Michel V. NGF induces pulmonary arterial hyperreactivity through Connexin 43 increased expression. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Bolea G, Philouze C, Risdon S, Dubois M, Humberclaude A, Ginies C, Geny B, Arnaud C, Dufour C, Meyer G. n-6 Polyunsaturated fatty acid oxidation increase oxidative stress, endothelial dysfunction and atherosclerosis in ApoE mice fed with chronic Western diet. Prevention strategy by apple polyphenols. Archives of Cardiovascular Diseases Supplements 2020. [DOI: 10.1016/j.acvdsp.2020.03.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Marion O, Lhomme S, Nayrac M, Dubois M, Pucelle M, Requena M, Migueres M, Abravanel F, Peron JM, Carrere N, Suc B, Delobel P, Kamar N, Izopet J. Hepatitis E virus replication in human intestinal cells. Gut 2020; 69:901-910. [PMID: 31727684 DOI: 10.1136/gutjnl-2019-319004] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 10/29/2019] [Accepted: 10/30/2019] [Indexed: 12/13/2022]
Abstract
OBJECTIVE Hepatitis E virus (HEV), one of the most common agent of acute hepatitis worldwide, is mainly transmitted enterically, via contaminated water for HEV genotypes 1 (HEV1) and HEV2, or by eating raw or undercooked infected meat for HEV genotype 3 (HEV3) and HEV4. However, little is known about how the ingested HEV reaches the liver or its ability to replicate in intestinal cells. DESIGN We developed human primary cultures of small intestine epithelial cells and intestinal explants obtained from small bowel resections. The epithelial cells were also polarised on transwells. Cells were infected with Kernow-p6 strain or clinically derived virions. RESULTS Primary intestinal cells supported the growth of Kernow-p6 strain and HEV1 and HEV3 clinically derived virions. Polarised enterocytes infected with HEV1 and HEV3 strains released HEV particles vectorially: mostly into the apical compartment with a little basally. Iodixanol density gradient centrifugation of enterocyte-derived HEV virions gave bands at a density of 1.06-1.08 g/cm3, corresponding to that of quasi-enveloped HEV particles. Ribavirin therapy inhibited HEV excretion from the basal surface but not from the apical side of infected human enterocytes. HEV virions also infected intestinal tissue explants. Lastly, HEV RNA and antigen were detected in the intestinal crypts of a chronically infected patient. CONCLUSION HEV can replicate in intestinal cells and reaches the liver as quasi-enveloped virions.
Collapse
Affiliation(s)
- Olivier Marion
- Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, Toulouse, France.,INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Paul Sabatier University, Toulouse, France
| | - Sebastien Lhomme
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Paul Sabatier University, Toulouse, France.,Virology Laboratory, National Reference Center for hepatitis E virus, Toulouse Purpan University Hospital, Toulouse, France
| | - Manon Nayrac
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France
| | - Martine Dubois
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Virology Laboratory, National Reference Center for hepatitis E virus, Toulouse Purpan University Hospital, Toulouse, France
| | - Mélanie Pucelle
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Virology Laboratory, National Reference Center for hepatitis E virus, Toulouse Purpan University Hospital, Toulouse, France
| | - Mary Requena
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Virology Laboratory, National Reference Center for hepatitis E virus, Toulouse Purpan University Hospital, Toulouse, France
| | - Marion Migueres
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Virology Laboratory, National Reference Center for hepatitis E virus, Toulouse Purpan University Hospital, Toulouse, France
| | - Florence Abravanel
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Paul Sabatier University, Toulouse, France.,Virology Laboratory, National Reference Center for hepatitis E virus, Toulouse Purpan University Hospital, Toulouse, France
| | - Jean Marie Peron
- Paul Sabatier University, Toulouse, France.,Hepatology and Gastroenterology Department, Toulouse Rangueil University Hospital, Toulouse, France
| | - Nicolas Carrere
- Paul Sabatier University, Toulouse, France.,Digestive Surgery Department, Toulouse Rangueil University Hospital, Toulouse, France
| | - Bertrand Suc
- Paul Sabatier University, Toulouse, France.,Digestive Surgery Department, Toulouse Rangueil University Hospital, Toulouse, France
| | - Pierre Delobel
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Paul Sabatier University, Toulouse, France.,Department of Infectious and Tropical Diseases, Toulouse Purpan University Hospital, Toulouse, France
| | - Nassim Kamar
- Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, Toulouse, France.,INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France.,Paul Sabatier University, Toulouse, France
| | - Jacques Izopet
- INSERM UMR1043, Center for Pathophysiology of Toulouse Purpan, Toulouse, France .,Paul Sabatier University, Toulouse, France.,Virology Laboratory, National Reference Center for hepatitis E virus, Toulouse Purpan University Hospital, Toulouse, France
| |
Collapse
|
25
|
Dimeglio C, Loubes JM, Deporte B, Dubois M, Latour J, Mansuy JM, Izopet J. The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France. J Infect 2020; 81:318-356. [PMID: 32360497 PMCID: PMC7189187 DOI: 10.1016/j.jinf.2020.04.031] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 04/21/2020] [Accepted: 04/22/2020] [Indexed: 11/26/2022]
Abstract
A new virus, SARS-CoV-2, has spread world-wide since December 2019, probably affecting millions of people and killing thousands. Failure to anticipate the spread of the virus now seriously threatens many health systems. We have designed a model for predicting the evolution of the SARS-CoV-2 epidemic in France, which is based on seroprevalence and makes it possible to anticipate the deconfinement strategy.
Collapse
Affiliation(s)
- Chloé Dimeglio
- UMR Inserm, U1043; UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse 31300, France; CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300 France.
| | - Jean-Michel Loubes
- Université de Toulouse, Institut de Mathématiques de Toulouse, Toulouse 31400, France
| | - Benjamin Deporte
- Université de Toulouse, Institut de Mathématiques de Toulouse, Toulouse 31400, France
| | - Martine Dubois
- UMR Inserm, U1043; UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse 31300, France; CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300 France
| | - Justine Latour
- CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300 France
| | | | - Jacques Izopet
- UMR Inserm, U1043; UMR CNRS, U5282, Centre de Physiopathologie de Toulouse Purpan (CPTP), Toulouse 31300, France; CHU Toulouse, Hôpital Purpan, Virology Laboratory, 31300 France
| |
Collapse
|
26
|
Poret B, Desrues L, Bonin MA, Pedard M, Dubois M, Leduc R, Modzelewski R, Decazes P, Morin F, Vera P, Castel H, Bohn P, Gandolfo P. Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours. Biomolecules 2020; 10:biom10030471. [PMID: 32204509 PMCID: PMC7175314 DOI: 10.3390/biom10030471] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Revised: 03/17/2020] [Accepted: 03/18/2020] [Indexed: 12/11/2022] Open
Abstract
Overexpression of G protein-coupled receptors (GPCRs) in tumours is widely used to develop GPCR-targeting radioligands for solid tumour imaging in the context of diagnosis and even treatment. The human vasoactive neuropeptide urotensin II (hUII), which shares structural analogies with somatostatin, interacts with a single high affinity GPCR named UT. High expression of UT has been reported in several types of human solid tumours from lung, gut, prostate, or breast, suggesting that UT is a valuable novel target to design radiolabelled hUII analogues for cancer diagnosis. In this study, two original urotensinergic analogues were first conjugated to a DOTA chelator via an aminohexanoic acid (Ahx) hydrocarbon linker and then -hUII and DOTA-urantide, complexed to the radioactive metal indium isotope to successfully lead to radiolabelled DOTA-Ahx-hUII and DOTA-Ahx-urantide. The 111In-DOTA-hUII in human plasma revealed that only 30% of the radioligand was degraded after a 3-h period. DOTA-hUII and DOTA-urantide exhibited similar binding affinities as native peptides and relayed calcium mobilization in HEK293 cells expressing recombinant human UT. DOTA-hUII, not DOTA-urantide, was able to promote UT internalization in UT-expressing HEK293 cells, thus indicating that radiolabelled 111In-DOTA-hUII would allow sufficient retention of radioactivity within tumour cells or radiolabelled DOTA-urantide may lead to a persistent binding on UT at the plasma membrane. The potential of these radioligands as candidates to target UT was investigated in adenocarcinoma. We showed that hUII stimulated the migration and proliferation of both human lung A549 and colorectal DLD-1 adenocarcinoma cell lines endogenously expressing UT. In vivo intravenous injection of 111In-DOTA-hUII in C57BL/6 mice revealed modest organ signals, with important retention in kidney. 111In-DOTA-hUII or 111In-DOTA-urantide were also injected in nude mice bearing heterotopic xenografts of lung A549 cells or colorectal DLD-1 cells both expressing UT. The observed significant renal uptake and low tumour/muscle ratio (around 2.5) suggest fast tracer clearance from the organism. Together, DOTA-hUII and DOTA-urantide were successfully radiolabelled with 111Indium, the first one functioning as a UT agonist and the second one as a UT-biased ligand/antagonist. To allow tumour-specific targeting and prolong body distribution in preclinical models bearing some solid tumours, these radiolabelled urotensinergic analogues should be optimized for being used as potential molecular tools for diagnosis imaging or even treatment tools.
Collapse
Affiliation(s)
- Benjamin Poret
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France; (B.P.); (L.D.); (M.P.); (M.D.); (F.M.); (P.G.)
- EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France; (R.M.); (P.D.); (P.V.); (P.B.)
- Department of Physiology & Pharmacology, Institute of Sherbrooke, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada; (M.-A.B.); (R.L.)
| | - Laurence Desrues
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France; (B.P.); (L.D.); (M.P.); (M.D.); (F.M.); (P.G.)
- EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France; (R.M.); (P.D.); (P.V.); (P.B.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Marc-André Bonin
- Department of Physiology & Pharmacology, Institute of Sherbrooke, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada; (M.-A.B.); (R.L.)
| | - Martin Pedard
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France; (B.P.); (L.D.); (M.P.); (M.D.); (F.M.); (P.G.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Martine Dubois
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France; (B.P.); (L.D.); (M.P.); (M.D.); (F.M.); (P.G.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Richard Leduc
- Department of Physiology & Pharmacology, Institute of Sherbrooke, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC J1H 5N4, Canada; (M.-A.B.); (R.L.)
| | - Romain Modzelewski
- EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France; (R.M.); (P.D.); (P.V.); (P.B.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Pierre Decazes
- EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France; (R.M.); (P.D.); (P.V.); (P.B.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Fabrice Morin
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France; (B.P.); (L.D.); (M.P.); (M.D.); (F.M.); (P.G.)
- EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France; (R.M.); (P.D.); (P.V.); (P.B.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Pierre Vera
- EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France; (R.M.); (P.D.); (P.V.); (P.B.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Hélène Castel
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France; (B.P.); (L.D.); (M.P.); (M.D.); (F.M.); (P.G.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
- Correspondence: ; Tel.: +(33)-2-35-14-66-23
| | - Pierre Bohn
- EA 4108, Laboratory of Computer Science, Information Processing and Systems (LITIS), team “QuantIF”, Centre Henri Becquerel, 76000 Rouen, France; (R.M.); (P.D.); (P.V.); (P.B.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| | - Pierrick Gandolfo
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, INSERM U1239, DC2N, 76000 Rouen, France; (B.P.); (L.D.); (M.P.); (M.D.); (F.M.); (P.G.)
- Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen, France
| |
Collapse
|
27
|
Lhomme S, Nicot F, Jeanne N, Dimeglio C, Roulet A, Lefebvre C, Carcenac R, Manno M, Dubois M, Peron JM, Alric L, Kamar N, Abravanel F, Izopet J. Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus. Front Microbiol 2020; 11:1. [PMID: 32082274 PMCID: PMC7004952 DOI: 10.3389/fmicb.2020.00001] [Citation(s) in RCA: 112] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 01/03/2020] [Indexed: 12/27/2022] Open
Abstract
Recombinant strains of hepatitis E virus (HEV) with insertions of human genomic fragments or HEV sequence duplications in the sequence encoding the polyproline region (PPR) were previously described in chronically infected patients. Such genomic rearrangements confer a replicative advantage in vitro but little is known about their frequency, location, or origin. As the sequences of only a few virus genomes are available, we analyzed the complete genomes of 114 HEV genotype 3 strains from immunocompromised (n = 85) and immunocompetent (n = 29) patients using the single molecular real-time sequencing method to determine the frequency, location, and origin of inserted genomic fragments, plus the proportions of variants with genomic rearrangements in each virus quasispecies. We also examined the amino acid compositions and post-translational modifications conferred by these rearrangements by comparing them to sequences without human gene insertions or HEV gene duplications. We found genomic rearrangements in 7/114 (6.1%) complete genome sequences (4 HEV-3f, 1 HEV-3e, 1 HEV-3 h, and 1 HEV-3chi-new), all from immunocompromised patients, and 3/7 were found at the acute phase of infection. Six of the seven patients harbored virus-host recombinant variants, including one patient with two different recombinant variants. We also detected three recombinant variants with genome duplications of the PPR or PPR + X domains in a single patient. All the genomic rearrangements (seven human fragment insertions of varying origins and three HEV genome duplications) occurred in the PPR. The sequences with genomic rearrangements had specific characteristics: increased net load (p < 0.001) and more ubiquitination (p < 0.001), phosphorylation (p < 0.001), and acetylation (p < 0.001) sites. The human fragment insertions and HEV genome duplications had slightly different characteristics. We believe this is the first description of HEV strains with genomic rearrangements in patients at the acute phase of infection; perhaps these strains are directly transmitted. Clearly, genomic rearrangements produce a greater net load with duplications and insertions having different features. Further studies are needed to clarify the mechanisms by which such modifications influence HEV replication.
Collapse
Affiliation(s)
- Sébastien Lhomme
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,INSERM, U1043, Toulouse, France.,Université Toulouse III-Paul Sabatier, Toulouse, France
| | - Florence Nicot
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Nicolas Jeanne
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Chloé Dimeglio
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Alain Roulet
- Plateforme Génomique, Centre INRA Occitanie-Toulouse, Castanet-Tolosan, France
| | - Caroline Lefebvre
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Romain Carcenac
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Maxime Manno
- Plateforme Génomique, Centre INRA Occitanie-Toulouse, Castanet-Tolosan, France
| | - Martine Dubois
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Jean-Marie Peron
- Service de Gastroentérologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Laurent Alric
- Service de médecine interne, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Nassim Kamar
- INSERM, U1043, Toulouse, France.,Université Toulouse III-Paul Sabatier, Toulouse, France.,Service de néphrologie, Dialyse et Transplantation d'Organe, Hôpital Rangueil, CHU de Toulouse, Toulouse, France
| | - Florence Abravanel
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,INSERM, U1043, Toulouse, France.,Université Toulouse III-Paul Sabatier, Toulouse, France
| | - Jacques Izopet
- Laboratoire de Virologie, Centre National de Référence du virus de l'hépatite E, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,INSERM, U1043, Toulouse, France.,Université Toulouse III-Paul Sabatier, Toulouse, France
| |
Collapse
|
28
|
Capelli N, Dubois M, Pucelle M, Da Silva I, Lhomme S, Abravanel F, Chapuy-Regaud S, Izopet J. Optimized Hepatitis E Virus (HEV) Culture and its Application to Measurements of HEV Infectivity. Viruses 2020; 12:v12020139. [PMID: 31991673 PMCID: PMC7077187 DOI: 10.3390/v12020139] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Revised: 01/08/2020] [Accepted: 01/21/2020] [Indexed: 02/07/2023] Open
Abstract
Hepatitis E virus (HEV) is a major concern in public health worldwide. Infections with HEV genotypes 3, 4, or 7 can lead to chronic hepatitis while genotype 1 infections can trigger severe hepatitis in pregnant women. Infections with all genotypes can worsen chronic liver diseases. As virions are lipid-associated in blood and naked in feces, efficient methods of propagating HEV clinical strains in vitro and evaluating the infectivity of both HEV forms are needed. We evaluated the spread of clinical strains of HEV genotypes 1 (HEV1) and 3 (HEV3) by quantifying viral RNA in culture supernatants and cell lysates. Infectivity was determined by endpoint dilution and calculation of the tissue culture infectious dose 50 (TCID50). An enhanced HEV production could be obtained varying the composition of the medium, including fetal bovine serum (FBS) and dimethylsulfoxide (DMSO) content. This increased TCID50 from 10 to 100-fold and allowed us to quantify HEV1 infectivity. These optimized methods for propagating and measuring HEV infectivity could be applied to health safety processes and will be useful for testing new antiviral drugs.
Collapse
Affiliation(s)
- Nicolas Capelli
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
- Centre de Physiopathologie de Toulouse Purpan (CPTP), Institut National de la Santé et de la Recherche Médicale, Inserm UMR1043, Centre National de la Recherche Scientifique, CNRS UMR5282, Université de Toulouse, 31024 Toulouse, France
| | - Martine Dubois
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
- Centre de Physiopathologie de Toulouse Purpan (CPTP), Institut National de la Santé et de la Recherche Médicale, Inserm UMR1043, Centre National de la Recherche Scientifique, CNRS UMR5282, Université de Toulouse, 31024 Toulouse, France
| | - Mélanie Pucelle
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
| | - Isabelle Da Silva
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
| | - Sébastien Lhomme
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
- Centre de Physiopathologie de Toulouse Purpan (CPTP), Institut National de la Santé et de la Recherche Médicale, Inserm UMR1043, Centre National de la Recherche Scientifique, CNRS UMR5282, Université de Toulouse, 31024 Toulouse, France
| | - Florence Abravanel
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
- Centre de Physiopathologie de Toulouse Purpan (CPTP), Institut National de la Santé et de la Recherche Médicale, Inserm UMR1043, Centre National de la Recherche Scientifique, CNRS UMR5282, Université de Toulouse, 31024 Toulouse, France
| | - Sabine Chapuy-Regaud
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
- Centre de Physiopathologie de Toulouse Purpan (CPTP), Institut National de la Santé et de la Recherche Médicale, Inserm UMR1043, Centre National de la Recherche Scientifique, CNRS UMR5282, Université de Toulouse, 31024 Toulouse, France
- Correspondence: ; Tel.: +33-567-690-431
| | - Jacques Izopet
- Department of Virology, National Reference Center for HEV, CHU Purpan, 31059 Toulouse, France
- Centre de Physiopathologie de Toulouse Purpan (CPTP), Institut National de la Santé et de la Recherche Médicale, Inserm UMR1043, Centre National de la Recherche Scientifique, CNRS UMR5282, Université de Toulouse, 31024 Toulouse, France
| |
Collapse
|
29
|
Dubois M, Faiz S, Vicentini C, Carpentier O, Mortier L. Réaction locale au rituximab. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
30
|
Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, Winocur G, De Ruiter M, Castel H. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 2019; 30:1925-1940. [PMID: 31617564 PMCID: PMC8109411 DOI: 10.1093/annonc/mdz410] [Citation(s) in RCA: 255] [Impact Index Per Article: 51.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Advances in diagnostic and therapeutic strategies in oncology have significantly increased the chance of survival of cancer patients, even those with metastatic disease. However, cancer-related cognitive impairment (CRCI) is frequently reported in patients treated for non-central nervous system cancers, particularly during and after chemotherapy. DESIGN This review provides an update of the state of the art based on PubMed searches between 2012 and March 2019 on 'cognition', 'cancer', 'antineoplastic agents' or 'chemotherapy'. It includes the most recent clinical, imaging and pre-clinical data and reports management strategies of CRCI. RESULTS Evidence obtained primarily from studies on breast cancer patients highlight memory, processing speed, attention and executive functions as the most cognitive domains impaired post-chemotherapy. Recent investigations established that other cancer treatments, such as hormone therapies and targeted therapies, can also induce cognitive deficits. Knowledge regarding predisposing factors, biological markers or brain functions associated with CRCI has improved. Factors such as age and genetic polymorphisms of apolipoprotein E, catechol-O-methyltransferase and BDNF may predispose individuals to a higher risk of cognitive impairment. Poor performance on neuropsychological tests were associated with volume reduction in grey matter, less connectivity and activation after chemotherapy. In animals, hippocampus-based memory and executive functions, mediated by the frontal lobes, were shown to be particularly susceptible to the effects of chemotherapy. It involves altered neurogenesis, mitochondrial dysfunction or brain cytokine response. An important next step is to identify strategies for managing cognitive difficulties, with primary studies to assess cognitive training and physical exercise regimens. CONCLUSIONS CRCI is not limited to chemotherapy. A multidisciplinary approach has improved our knowledge of the complex mechanisms involved. Nowadays, studies evaluating cognitive rehabilitation programmes are encouraged to help patients cope with cognitive difficulties and improve quality of life during and after cancer.
Collapse
Affiliation(s)
- M. Lange
- INSERM, U1086, ANTICIPE, 14000 Caen,Clinical Research Department, Centre François Baclesse, 14000 Caen,Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen
| | - F. Joly
- INSERM, U1086, ANTICIPE, 14000 Caen,Clinical Research Department, Centre François Baclesse, 14000 Caen,Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen,Medical Oncology Department, CHU de Caen, 14000 Caen, France,Correspondence to: Prof. Florence Joly, Medical Oncology Department, Inserm U1086 Anticipe, Centre François Baclesse, 3 avenue Général Harris, Caen 14000, France. Tel: +33-2-3145-5002;
| | - J Vardy
- Concord Cancer Centre, Concord Repatriation General Hospital, Sydney, New South Wales,Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
| | - T. Ahles
- Neurocognitive Research Lab, Memorial Sloan Kettering Cancer Center, New York, USA
| | - M. Dubois
- Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen,Normandie University, UNIROUEN, INSERM, DC2N, 76000 Rouen,Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen
| | - L. Tron
- INSERM, U1086, ANTICIPE, 14000 Caen,Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen,CHU de Caen, 14000 Caen, France
| | - G. Winocur
- Baycrest Centre, Rotman Research Institute, Toronto,Department of Psychology, Trent University, Peterborough,Department of Psychology and Psychiatry, University of Toronto, Toronto, Canada
| | - M.B. De Ruiter
- Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - H. Castel
- Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen,Normandie University, UNIROUEN, INSERM, DC2N, 76000 Rouen,Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen
| |
Collapse
|
31
|
Dubois M, Dezoteux F, Greliak A, Vicentini C, Étienne N, Lefevre G, Pontana F, Staumont-Sallé D, Mortier L. Myocardite à éosinophiles sous nivolumab concomitante d’une réponse partielle carcinologique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Dubois M, Abi Rached H, Vicentini C, Maire C, Mordon S, Mortier L. Traitement des kératoses actiniques du cuir chevelu par le dispositif de photothérapie dynamique textile Fluxmedicare® : évaluation en vraie vie sur 32 patients. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Royer G, Decousser JW, Branger C, Dubois M, Médigue C, Denamur E, Vallenet D. PlaScope: a targeted approach to assess the plasmidome from genome assemblies at the species level. Microb Genom 2019; 4. [PMID: 30265232 PMCID: PMC6202455 DOI: 10.1099/mgen.0.000211] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Plasmid prediction may be of great interest when studying bacteria of medical importance such as Enterobacteriaceae as well as Staphylococcus aureus or Enterococcus. Indeed, many resistance and virulence genes are located on such replicons with major impact in terms of pathogenicity and spreading capacities. Beyond strain outbreak, plasmid outbreaks have been reported in particular for some extended-spectrum beta-lactamase- or carbapenemase-producing Enterobacteriaceae. Several tools are now available to explore the ‘plasmidome’ from whole-genome sequences with various approaches, but none of them are able to combine high sensitivity and specificity. With this in mind, we developed PlaScope, a targeted approach to recover plasmidic sequences in genome assemblies at the species or genus level. Based on Centrifuge, a metagenomic classifier, and a custom database containing complete sequences of chromosomes and plasmids from various curated databases, PlaScope classifies contigs from an assembly according to their predicted location. Compared to other plasmid classifiers, PlasFlow and cBar, it achieves better recall (0.87), specificity (0.99), precision (0.96) and accuracy (0.98) on a dataset of 70 genomes of Escherichia coli containing plasmids. In a second part, we identified 20 of the 21 chromosomal integrations of the extended-spectrum beta-lactamase coding gene in a clinical dataset of E. coli strains. In addition, we predicted virulence gene and operon locations in agreement with the literature. We also built a database for Klebsiella and correctly assigned the location for the majority of resistance genes from a collection of 12 Klebsiella pneumoniae strains. Similar approaches could also be developed for other well-characterized bacteria.
Collapse
Affiliation(s)
- G Royer
- 2Université Paris Diderot, INSERM, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France.,3LABGeM, Génomique Métabolique, Genoscope, Institut François Jacob, CEA, CNRS, Univ Evry, Université Paris-Saclay, 91057 Evry, France.,1Département de Microbiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Université Paris Est Créteil, F-94000 Créteil, France
| | - J W Decousser
- 2Université Paris Diderot, INSERM, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France.,1Département de Microbiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, Université Paris Est Créteil, F-94000 Créteil, France
| | - C Branger
- 2Université Paris Diderot, INSERM, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France
| | - M Dubois
- 3LABGeM, Génomique Métabolique, Genoscope, Institut François Jacob, CEA, CNRS, Univ Evry, Université Paris-Saclay, 91057 Evry, France
| | - C Médigue
- 3LABGeM, Génomique Métabolique, Genoscope, Institut François Jacob, CEA, CNRS, Univ Evry, Université Paris-Saclay, 91057 Evry, France
| | - E Denamur
- 4Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Laboratoire de Génétique Moléculaire, F-75018 Paris, France.,2Université Paris Diderot, INSERM, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France
| | - D Vallenet
- 3LABGeM, Génomique Métabolique, Genoscope, Institut François Jacob, CEA, CNRS, Univ Evry, Université Paris-Saclay, 91057 Evry, France
| |
Collapse
|
34
|
Castel H, Al Sagheer T, Dubois M, Campart C, Desrues L, Lange M, Gandolfo P, Joly F. Impact of hormone-therapy used in CRPC patients: Evaluation of abiraterone acetate/prednisone or enzalutamide on activity and cognitive functions in aged castrated mice. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e16526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16526 Background: Prostate cancer (PC) is a major public health problem and represents the most frequent cancer in elderly male patients. Although most patients initially respond to androgen deprivation therapy (ADT) through inhibition of gonadal testosterone biosynthesis, the majority of these patients will progress to metastatic castration-resistant PC (mCRPC). Novel oral agents targeting androgen signaling axis, abiraterone acetate (AA)+prednisone (P) and enzalutamide (ENZ) are available and used in mCRPC patients in addition to ADT, but their impact on cognition is not well understood. Recently, the AQUARiUS study (Thiery-Vuillemin et al., ESMO Open, 2018) showed that after treatment, median Quality of life score improved with AAP. Additionally, results from a phase 2 trial showed that a worsening of depression symptoms were more often detected in ENZ- than in AAP-treated patients (Khalaf et al., Eur Urol, 2018). Methods: Here we developed a preclinical animal model to clarify the potential impact of AAP or ENZ on emotional reactivity and cognitive functions including spontaneous activity, anxiety-like and depression-like behaviors or spatial memory and learning. Results: In aged castrated mice receiving per os vehicle or AAP or ENZ, we showed that, in contrast to AAP, exposure to ENZ reduced spontaneous activity and increased depressive-like behaviors. AAP-treated mice displayed diminished self-grooming suggesting lower arousal in a novel environment. None of the treatments provoked anxiety-like behavior, learning and memory deficits. However, the swimming strategies (Morris-water maze) in AAP and ENZ groups were slightly altered. Analysis of plasma from treated mice revealed a detectable level of corticosterone only in AAP group. Conclusions: These data establish the impact of ENZ on emotional reactivity and of both ENZ and AAP on subtle cognitive functions in castrated aged male subjects. It paves the road for future effective research that could lead to better management of quality of life in mCRPC.
Collapse
Affiliation(s)
| | | | | | | | | | - Marie Lange
- INSERM 1086, Centre François Baclesse, Caen, France
| | | | - Florence Joly
- U1086 Inserm ANTICIPE and Baclesse center, Caen, France
| |
Collapse
|
35
|
Cardouat G, Douard M, Robillard P, Dubois M, Marthan R, Muller B, Guibert C, Freund-Michel V. Short-term mechanisms activated by the nerve growth factor NGF to induce pulmonary arterial hyperreactivity. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2019.02.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
36
|
Marion O, Capelli N, Lhomme S, Dubois M, Pucelle M, Abravanel F, Kamar N, Izopet J. Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. J Infect 2019; 78:232-240. [PMID: 30659856 DOI: 10.1016/j.jinf.2019.01.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 12/17/2018] [Accepted: 01/12/2019] [Indexed: 12/23/2022]
Abstract
OBJECTIVES Hepatitis E virus genotype 3 (HEV3) is responsible for acute and chronic liver disease in solid organ transplant (SOT) recipients. HEV was recently found in the urine of some acutely and chronically genotype 4-infected patients. METHODS We examined the urinary excretion of HEV3 by 24 consecutive SOT recipients at the acute phase of HEV hepatitis and characterized the excreted virus. RESULTS Urinary HEV RNA was detected in 12 (50%) of the 24 transplanted patients diagnosed with HEV hepatitis. Urinary HEV antigen (Ag) was detected in all but one of the patients (96%). The density of RNA-containing HEV particles in urine was low (1.11-1.12 g/cm3), corresponding to lipid-associated virions. The urinary HEV RNA/Ag detected was not associated with impaired kidney function or de novo proteinuria. Finally, there was more HEV Ag in the serum at the acute phase of HEV infection in SOT recipients whose infection became chronic. CONCLUSIONS HEV3 excreted via the urine of SOT recipients at the acute phase of HEV hepatitis has a lipid envelope. Renal function was not impaired. While urinary HEV Ag was a sensitive indicator of HEV infection, only acute phase serum HEV Ag indicated the development of a chronic infection.
Collapse
Affiliation(s)
- Olivier Marion
- Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; Inserm UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France
| | - Nicolas Capelli
- Inserm UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France; Laboratory of Virology, CHU Purpan, Toulouse, France
| | - Sebastien Lhomme
- Inserm UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France; Laboratory of Virology, CHU Purpan, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Martine Dubois
- Inserm UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France; Laboratory of Virology, CHU Purpan, Toulouse, France
| | | | - Florence Abravanel
- Inserm UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France; Laboratory of Virology, CHU Purpan, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Nassim Kamar
- Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France; Inserm UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France; Université Paul Sabatier, Toulouse, France
| | - Jacques Izopet
- Inserm UMR1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France; Laboratory of Virology, CHU Purpan, Toulouse, France; Université Paul Sabatier, Toulouse, France.
| |
Collapse
|
37
|
Pilard C, Dubois M, Renesme L, Quignard J, Marthan R, Muller B, Guibert C, Dumas De La Roque E. Effects of celastrol in a mouse model of pulmonary hypertension associated with bronchopulmonary dysplasia induced by hyperoxia. Archives of Cardiovascular Diseases Supplements 2019. [DOI: 10.1016/j.acvdsp.2018.10.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Dupré D, Dubois M, Tcherkassof A. Rôle de l’émotion dans l’acceptabilité d’un produit : évaluation des composantes cognitive, motivationnelle et subjective. Psychologie du Travail et des Organisations 2018. [DOI: 10.1016/j.pto.2017.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
39
|
Dubois M, Bataille B, Carlier D, Gras L, Tokarski M, Bonafos G, Demailly FX, Darloy F, Mortier L, Desmedt E. Radiothérapie de contact dans le traitement de carcinomes périoculaires : résultats carcinologiques et cosmétiques du centre Léonard-de-Vinci de Dechy. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Gouilly J, Chen Q, Siewiera J, Cartron G, Levy C, Dubois M, Al-Daccak R, Izopet J, Jabrane-Ferrat N, El Costa H. Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface. Nat Commun 2018; 9:4748. [PMID: 30420629 PMCID: PMC6232144 DOI: 10.1038/s41467-018-07200-2] [Citation(s) in RCA: 74] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2017] [Accepted: 10/03/2018] [Indexed: 02/07/2023] Open
Abstract
Hepatitis E virus (HEV) infection, particularly HEV genotype 1 (HEV-1), can result in fulminant hepatic failure and severe placental diseases, but mechanisms underlying genotype-specific pathogenicity are unclear and appropriate models are lacking. Here, we model HEV-1 infection ex vivo at the maternal-fetal interface using the decidua basalis and fetal placenta, and compare its effects to the less-pathogenic genotype 3 (HEV-3). We demonstrate that HEV-1 replicates more efficiently than HEV-3 both in tissue explants and stromal cells, produces more infectious progeny virions and causes severe tissue alterations. HEV-1 infection dysregulates the secretion of several soluble factors. These alterations to the cytokine microenvironment correlate with viral load and contribute to the tissue damage. Collectively, this study characterizes an ex vivo model for HEV infection and provides insights into HEV-1 pathogenesis during pregnancy that are linked to high viral replication, alteration of the local secretome and induction of tissue injuries.
Collapse
Affiliation(s)
- Jordi Gouilly
- Centre of Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR5282, Toulouse III University, 31024, Toulouse, France
| | - Qian Chen
- Centre of Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR5282, Toulouse III University, 31024, Toulouse, France
| | - Johan Siewiera
- University of California San Francisco, School of Medicine, Laboratory of Medicine, San Francisco, CA, USA
| | - Géraldine Cartron
- Service de Gynécologie-Obstétrique, Hôpital Paule de Viguier, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Claude Levy
- Service de Gynécologie-Obstétrique, Clinique Sarrus-Teinturiers, 31300, Toulouse, France
| | - Martine Dubois
- Laboratoire de Virologie, Institute of Federative Biology, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Reem Al-Daccak
- INSERM UMRS976, Université Paris Diderot, Hôpital Saint-Louis, 75010, Paris, France
| | - Jacques Izopet
- Centre of Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR5282, Toulouse III University, 31024, Toulouse, France
- Laboratoire de Virologie, Institute of Federative Biology, Centre Hospitalier Universitaire, 31059, Toulouse, France
| | - Nabila Jabrane-Ferrat
- Centre of Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR5282, Toulouse III University, 31024, Toulouse, France.
| | - Hicham El Costa
- Centre of Pathophysiology Toulouse Purpan, INSERM U1043, CNRS UMR5282, Toulouse III University, 31024, Toulouse, France.
- Laboratoire de Virologie, Institute of Federative Biology, Centre Hospitalier Universitaire, 31059, Toulouse, France.
| |
Collapse
|
41
|
Abravanel F, Lacipière A, Lhomme S, Dubois M, Minier L, Peron JM, Alric L, Kamar N, Izopet J. Performance of a commercial assay for detecting and quantifying HEV RNA in faeces. J Clin Virol 2018; 109:1-5. [PMID: 30336371 PMCID: PMC7106495 DOI: 10.1016/j.jcv.2018.10.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Revised: 10/05/2018] [Accepted: 10/09/2018] [Indexed: 01/11/2023]
Abstract
No commercial HEV RNA assay is validated for use in faecal samples. Monitoring HEV faecal excretion is recommended for managing chronic HEV infection in solid-organ transplant recipients. We evaluated the Altona assay by testing patients on ribavirin therapy.
Background Detecting hepatitis E virus (HEV) RNA in faeces is useful for diagnosing and monitoring HEV infections, particularly in immunocompromised patients requiring ribavirin therapy. Objectives This study evaluated the performance of the Altona RealStar HEV RNA kit for detecting and quantifying HEV in faeces. Study design RNA was extracted from 94 stool samples by two methods: QIAamp Viral RNA Mini kit and MagNA Pure 96 automate. The Altona results were compared to a reference laboratory-developed accredited ISO15189 RT-PCR assay. Results The Altona and reference assays detect HEV RNA in 77/93 (82.8%) and 83/93 (89.2%) of the QIAamp extracted samples, respectively, after exclusion of invalid result; they detected HEV RNA in 67/92 (72.8%) and 66/92 (71.7%) of the MagNA Pure extracted samples, respectively, which emphasizes the importance of the RNA extraction method. The HEV RNA concentrations obtained with Altona RT-PCR and the reference RT-PCR were well correlated whatever the extraction method, and Bland Altman analyses indicated that the Altona values were higher than the reference assay values. The Altona values for QIAamp-extracted and MagNA Pure-extracted HEV RNA were very similar. Conclusions The Altona RealStar assay is suitable for quantifying HEV RNA in the faeces and monitoring HEV RNA shedding during ribavirin therapy. Extraction is critical for detecting faecal HEV with high performance RT-PCR assays.
Collapse
Affiliation(s)
- Florence Abravanel
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France; CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France.
| | - Audrey Lacipière
- CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France
| | - Sébastien Lhomme
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France; CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France
| | - Martine Dubois
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France; CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France
| | - Luce Minier
- CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France
| | - Jean-Marie Peron
- CHU Toulouse, Hôpital Purpan, Département de Gastroentérologie, F-31300, France
| | - Laurent Alric
- CHU Toulouse, Hôpital Purpan, Service de médecine interne, F-31300, France
| | - Nassim Kamar
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France; CHU Toulouse, Hôpital Rangueil, Département de Néphrologie, Dialyse et Transplantation multi-organe, F-31300 France
| | - Jacques Izopet
- INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan, Toulouse, F-31300, France; CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, National Reference Center for Hepatitis E, F-31300, France
| |
Collapse
|
42
|
Clavier T, Mutel A, Desrues L, Lefevre-Scelles A, Gastaldi G, El Amki M, Dubois M, Melot A, Wurtz V, Curey S, Gérardin E, Proust F, Compère V, Castel H. Association between vasoactive peptide urotensin II in plasma and cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a potential therapeutic target. J Neurosurg 2018; 131:1-11. [PMID: 30497195 DOI: 10.3171/2018.4.jns172313] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Accepted: 04/23/2018] [Indexed: 01/07/2023]
Abstract
OBJECTIVECerebral vasospasm (VS) is a severe complication of aneurysmal subarachnoid hemorrhage (SAH). Urotensin II (UII) is a potent vasoactive peptide activating the urotensin (UT) receptor, potentially involved in brain vascular pathologies. The authors hypothesized that UII/UT system antagonism with the UT receptor antagonist/biased ligand urantide may be associated with post-SAH VS. The objectives of this study were 2-fold: 1) to leverage an experimental mouse model of SAH with VS in order to study the effect of urotensinergic system antagonism on neurological outcome, and 2) to investigate the association between plasma UII level and symptomatic VS after SAH in human patients.METHODSA mouse model of SAH was used to study the impacts of UII and the UT receptor antagonist/biased ligand urantide on VS and neurological outcome. Then a clinical study was conducted in the setting of a neurosurgical intensive care unit. Plasma UII levels were measured in SAH patients daily for 9 days, starting on the 1st day of hospitalization, and were compared with plasma UII levels in healthy volunteers.RESULTSIn the mouse model, urantide prevented VS as well as SAH-related fine motor coordination impairment. Seventeen patients with SAH and external ventricular drainage were included in the clinical study. The median plasma UII level was 43 pg/ml (IQR 14-80 pg/ml). There was no significant variation in the daily median plasma UII level (median value for the 17 patients) from day 0 to day 8. The median level of plasma UII during the 9 first days post-SAH was higher in patients with symptomatic VS than in patients without VS (77 pg/ml [IQR 33.5-111.5 pg/ml] vs 37 pg/ml [IQR 21-46 pg/ml], p < 0.05). Concerning daily measures of plasma UII levels in VS, non-VS patients, and healthy volunteers, we found a significant difference between SAH patients with VS (median 66 pg/ml [IQR 30-110 pg/ml]) and SAH patients without VS (27 pg/ml [IQR 15-46 pg/ml], p < 0.001) but no significant difference between VS patients and healthy volunteers (44 pg/ml [IQR 27-51 pg/ml]) or between non-VS patients and healthy volunteers.CONCLUSIONSThe results of this study suggest that UT receptor antagonism with urantide prevents VS and improves neurological outcome after SAH in mice and that an increase in plasma UII is associated with cerebral VS subsequent to SAH in humans. The causality link between circulating UII and VS after SAH remains to be established, but according to our data the UT receptor is a potential therapeutic target in SAH.
Collapse
Affiliation(s)
- Thomas Clavier
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- Departments of3Anesthesiology and Critical Care
| | - Alexandre Mutel
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
| | - Laurence Desrues
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
| | - Antoine Lefevre-Scelles
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- Departments of3Anesthesiology and Critical Care
| | | | - Mohamad El Amki
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
| | - Martine Dubois
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
| | - Anthony Melot
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
- 4Neurosurgery, and
| | - Véronique Wurtz
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- Departments of3Anesthesiology and Critical Care
| | | | - Emmanuel Gérardin
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
- 5Radiology, Rouen University Hospital, Rouen, France
| | - François Proust
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
- 4Neurosurgery, and
| | - Vincent Compère
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- Departments of3Anesthesiology and Critical Care
| | - Hélène Castel
- 1Normandie Université, UNIROUEN, INSERM, DC2N
- 2Institute for Research and Innovation in Biomedicine; and
| |
Collapse
|
43
|
Nicot F, Jeanne N, Roulet A, Lefebvre C, Carcenac R, Manno M, Dubois M, Kamar N, Lhomme S, Abravanel F, Izopet J. Diversity of hepatitis E virus genotype 3. Rev Med Virol 2018; 28:e1987. [PMID: 29939461 DOI: 10.1002/rmv.1987] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 05/12/2018] [Accepted: 05/21/2018] [Indexed: 12/27/2022]
Abstract
Hepatitis E virus genotype 3 (HEV-3) can lead to chronic infection in immunocompromised patients, and ribavirin is the treatment of choice. Recently, mutations in the polymerase gene have been associated with ribavirin failure but their frequency before treatment according to HEV-3 subtypes has not been studied on a large data set. We used single-molecule real-time sequencing technology to sequence 115 new complete genomes of HEV-3 infecting French patients. We analyzed phylogenetic relationships, the length of the polyproline region, and mutations in the HEV polymerase gene. Eighty-five (74%) were in the clade HEV-3efg, 28 (24%) in HEV-3chi clade, and 2 (2%) in HEV-3ra clade. Using automated partitioning of maximum likelihood phylogenetic trees, complete genomes were classified into subtypes. Polyproline region length differs within HEV-3 clades (from 189 to 315 nt). Investigating mutations in the polymerase gene, distinct polymorphisms between HEV-3 subtypes were found (G1634R in 95% of HEV-3e, G1634K in 56% of HEV-3ra, and V1479I in all HEV-3efg, clade HEV-3ra, and HEV-3k strains). Subtype-specific polymorphisms in the HEV-3 polymerase have been identified. Our study provides new complete genome sequences of HEV-3 that could be useful for comparing strains circulating in humans and the animal reservoir.
Collapse
Affiliation(s)
- Florence Nicot
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Nicolas Jeanne
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Alain Roulet
- Plateforme Génomique, Centre INRA Occitanie-Toulouse, Castanet-Tolosan, France
| | - Caroline Lefebvre
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Romain Carcenac
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Maxime Manno
- Plateforme Génomique, Centre INRA Occitanie-Toulouse, Castanet-Tolosan, France
| | - Martine Dubois
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France
| | - Nassim Kamar
- Center of Pathophysiology, Toulouse Purpan, INSERM, U1043, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France.,Service de néphrologie, Dialyse et Transplantation d'Organe, Hôpital Rangueil, CHU de Toulouse, Toulouse, France
| | - Sébastien Lhomme
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,Center of Pathophysiology, Toulouse Purpan, INSERM, U1043, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France
| | - Florence Abravanel
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,Center of Pathophysiology, Toulouse Purpan, INSERM, U1043, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France
| | - Jacques Izopet
- Centre National de Référence du virus de l'hépatite E, Laboratoire de Virologie, Hôpital Purpan, CHU de Toulouse, Toulouse, France.,Center of Pathophysiology, Toulouse Purpan, INSERM, U1043, Toulouse, France.,Université Toulouse III Paul-Sabatier, Toulouse, France
| |
Collapse
|
44
|
Brien M, Dubois M, Jobin V, Minville C, Boutin I, Vafrin T, Larochelle P, Marette A, Series F. 0443 Lipopolysaccharide Binding Protein (lbp) Is Associated With The Occurrence Of Cardio-metabolic Disturbances In Obstructive Sleep Apnea (osa). Sleep 2018. [DOI: 10.1093/sleep/zsy061.442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Douard M, Robillard P, Deweirdt J, Baudrimont I, Dubois M, Marthan R, Savineau J, Muller B, Guibert C, Freund-Michel V. Connexin-43 expression is increased by the nerve growth factor (NGF) and contributes to pulmonary arterial altered reactivity in pulmonary hypertension. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.156] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
46
|
Bolea G, Philouze C, Dubois M, Humberclaude A, Ginies C, Arnaud C, Meyer G, Dufour C. Apple polyphenols decrease endothelial dysfunction and atherosclerosis after chronic Western diet in a ApoE mouse model. Archives of Cardiovascular Diseases Supplements 2018. [DOI: 10.1016/j.acvdsp.2018.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
47
|
Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérant S, Bartélémy P, Pierard L, Fizazi K, Joly F. Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. BMC Cancer 2018; 18:110. [PMID: 29382311 PMCID: PMC5791194 DOI: 10.1186/s12885-017-3764-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Accepted: 11/09/2017] [Indexed: 11/17/2022] Open
Affiliation(s)
- Marie Lange
- INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076, Caen, France.,Clinical Research Department, Centre François Baclesse, 14076, Caen, France.,Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076, Caen, France
| | - Heidi Laviec
- Medical Oncology Department, Centre François Baclesse, 14076, Caen, France
| | - Hélène Castel
- Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076, Caen, France.,Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM, DC2N, 76000, Rouen, France
| | - Natacha Heutte
- INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076, Caen, France.,Clinical Research Department, Centre François Baclesse, 14076, Caen, France
| | - Alexandra Leconte
- Clinical Research Department, Centre François Baclesse, 14076, Caen, France
| | - Isabelle Léger
- INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076, Caen, France.,Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076, Caen, France.,UPO, Gustave Roussy, 94800, Villejuif, France.,NeuroHIV Rehabilitation Unit, Bicêtre University Hospital, 94275, Le Kremlin Bicêtre, France
| | - Bénédicte Giffard
- Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076, Caen, France.,Normandie University, UNICAEN, EPHE Paris, INSERM, U1077, 14000, Caen, France
| | - Aurélie Capel
- Clinical Research Department, Centre François Baclesse, 14076, Caen, France
| | - Martine Dubois
- Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076, Caen, France.,Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM, DC2N, 76000, Rouen, France
| | - Bénédicte Clarisse
- Clinical Research Department, Centre François Baclesse, 14076, Caen, France
| | - Elodie Coquan
- Clinical Research Department, Centre François Baclesse, 14076, Caen, France.,Medical Oncology Department, Centre François Baclesse, 14076, Caen, France
| | - Frédéric Di Fiore
- Medical Oncology Department, Centre Henri-Becquerel, 76000, Rouen, France.,Digestive and Urology Oncology Unit, Rouen University Hospital, 76000, Rouen, France
| | - Sophie Gouérant
- Medical Oncology Department, Centre Henri-Becquerel, 76000, Rouen, France.,Digestive and Urology Oncology Unit, Rouen University Hospital, 76000, Rouen, France
| | - Philippe Bartélémy
- Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France
| | - Laure Pierard
- Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg, 67000, Strasbourg, France
| | - Karim Fizazi
- Medical Oncology Department, Gustave Roussy, 94800, Villejuif, France
| | - Florence Joly
- INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, 14076, Caen, France. .,Clinical Research Department, Centre François Baclesse, 14076, Caen, France. .,Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14076, Caen, France. .,Medical Oncology Department, CHU de Caen, 14000, Caen, France.
| |
Collapse
|
48
|
Dubois M, Cousin E, Chouklati K, Bruneau B, Proisy M. Scurvy in a 3-year-old autistic girl: Whole-body magnetic resonance imaging findings. Diagn Interv Imaging 2018. [DOI: 10.1016/j.diii.2017.06.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
49
|
Herber M, Dubois M, Mertz P, Rougier E, Martin T, Gavand P, Korganow A, Toussaint E, Poindron V, Desprez D, Guffroy A. Syndrome de Willebrand acquis et lymphome splénique : réponse spectaculaire à la corticothérapie. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
50
|
Herber M, Rougier E, Mertz P, Dubois M, Poindron V, Korganow A, Martin T, Gavand P, Guffroy A. Pneumopathie atypique à Bocavirus humain de type 1 responsable d’un syndrome d’activation macrophagique chez un adulte immunodéprimé atteint d’une granulomatose avec polyangéite. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.10.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|